CI

At a glance

ClinicalIndex Comparison Record
N/ANot Yet Recruiting· 69 target
Drug / intervention
MTM-H-001 Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07476378
NCT07476378N/ANot Yet Recruiting
CompareCT.gov

An Open-label, Single-arm, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Efficacy of MTM-H-001 in the Treatment of Adult Participants With Relapsed or Refractory B-cell Malignancies (Archonc-001)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·interventional·Posted Mar 17, 2026·Updated Mar 17, 2026

In Brief

A clinical study evaluating MTM-H-001 Injection for Lymphoma, Large B-Cell, Diffuse (DLBCL) and 5 related conditions. Not yet recruiting, targeting 69 participants across 1 site.

Detailed Summary

This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with relapsed/refractory (R/R) B-cell malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular, Lymphoma, Mantle-Cell, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Lymphoma, B-Cell, Marginal Zone, Transformed Follicular Lymphoma (TFL)
CountriesChina
CollaboratorsMagicTime Medicine

Timeline

N/ANot Yet Recruiting
20272028
First PostedMar 17, 2026
Enrollment StartMar 1, 2026
Primary CompletionJan 1, 2028
Study CompletionJun 1, 2028
TodayJul 1, 2026
Enrollment to primary: 1.8 yearsPosted 3 months agoPrimary completion in 1.5 years

Interventions

MTM-H-001 Injectiondrug

Each participant receives MTM-H-001 Injection